Researchers at VIB, KU Leuven and UZ Leuven devised a novel approach to develop antibacterial drugs. With antibiotic resistance on the rise worldwide, such new drugs are urgently needed. The Flemish biotech spin-off Aelin Therapeutics will exploit the technology to produce new antibiotics for the clinic.
Around the world bacteria are developing new strategies that render them resistant to antibiotics, resulting in an increasing number of patients dying from untreatable infections. Experts now agree that unless we discover new medicines soon, the post-antibiotic era may be upon us, effectively pushing human healthcare back to the 1940s. In particular, a class of bacteria, Gram-negative bacteria, which include the well-known species E. coli, are causing major problems in hospitals.
The problem is that most antibiotics that we know today work according to only a few mechanisms of action and so when a bacterium becomes tolerant to one drug, it often becomes tolerant to the whole family. What we need to solve this situation is an entirely new class of drugs that shares no structural or mechanistic similarities with the existing antibiotics.
Professors Joost Schymkowitz and Frederic Rousseau of VIB-KU Leuven in collaboration with Johan Van Eldere of University Hospitals Leuven have gone one step further: they have developed a new way of designing antibiotic drugs that can give rise to many new antibacterial molecules.
These drugs penetrate bacterial cells where they induce a process called protein aggregation. This process resembles what happens when boiling an egg, but now without heat: proteins that normally need to carry out essential functions for the bacteria - such as digesting their food - clump together and can no longer carry out their work. As this affects many proteins in the bacterial cell all at once, the bacteria rapidly succumb and die.
In a recent publication in the highly regarded scientific journal Nature Communications, the scientists reveal novel molecules with a strong antibacterial activity against Gram-negative bacteria.
The technology will now be further explored and exploited by the Flemish start-up Aelin Therapeutics. Founded last December after attracting 27 million Euro in investments, this biotech company uses the protein aggregation approach (PeptinTM-technology) devised by Schymkowitz and Rousseau to develop new therapeutics.
Via Aelin Therapeutics, the lab findings will be applied to generate many more antibacterial molecules. The company aims to apply the same technology to target a wide array of other diseases.
Source: Flanders Institute for Biotechnology
A Helping Hand: Innovative Approaches to Expanding Hand Hygiene Programs in Acute Care Settings
July 9th 2025Who knew candy, UV lights, and a college kid in scrubs could double hand hygiene adherence? A Pennsylvania hospital’s creative shake-up of its infection prevention program shows that sometimes it takes more than soap to get hands clean—and keep them that way.
Broadening the Path: Diverse Educational Routes Into Infection Prevention Careers
July 4th 2025Once dominated by nurses, infection prevention now welcomes professionals from public health, lab science, and respiratory therapy—each bringing unique expertise that strengthens patient safety and IPC programs.
How Contaminated Is Your Stretcher? The Hidden Risks on Hospital Wheels
July 3rd 2025Despite routine disinfection, hospital surfaces, such as stretchers, remain reservoirs for harmful microbes, according to several recent studies. From high-touch areas to damaged mattresses and the effectiveness of antimicrobial coatings, researchers continue to uncover persistent risks in environmental hygiene, highlighting the critical need for innovative, continuous disinfection strategies in health care settings.